Pipeline
Compound
Platform
Indication
Phase I
Expansion Cohorts/Phase II
Pivotal Trial
Approval
Partner
Compound
Pidnarulex(CX-5461)
Platform
G-quadruplex(G4)
Indication
Breast cancer
Progress
CA
Partner
Dream team & CCTG
Compound
Pidnarulex(CX-5461)
Platform
G-quadruplex(G4)
Indication
Ovarian cancer /Breast/Other Cancer
Progress
CA
Partner
Compound
Pidnarulex(CX-5461)
Platform
G-quadruplex(G4)
Indication
Hematologic Malignancies
Progress
AU
Partner
PMCC
Compound
Silmitasertib(CX-4945)
Platform
CK2
Indication
Cholangiocarcinoma
Progress
USA KR TW
Partner
Compound
Silmitasertib(CX-4945)
Platform
CK2
Indication
Basal cell carcinoma(BCC)
Progress
USA
Partner
Compound
Silmitasertib(CX-4945)
Platform
CK2
Indication
Medulloblastoma(MB)
Progress
USA
Partner
PBTC/Stanford Univ.
Compound
Silmitasertib(CX-4945)
Platform
CK2
Indication
COVID-19
Progress
USA(IND)
Partner
Patent Portfolio
Senhwa’s patent portfolio is comprised of 110 issued patents and 31 pending patent applications. Intellectual property rights include patents covering product derivatives, pharmaceutical formulations, method of use, manufacturing process, crystalline forms and combination therapies.
Patents have been granted in the US, Europe, Canada, Japan, South Korea, China, Hong Kong, Russia, Australia, New Zealand and Taiwan. Especially in Europe, there are 19 countries that have been registered to extend the market size for cancer therapy, including Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey, United Kingdom.
